$INNOGEN-B(02591.HK) Everyone draws lots...
Overview
INNOGEN-B (2591)
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical...
- Open
- 3.450
- High
- 3.725
- Low
- 3.450
- Prev. Close
- 3.550
- Volume
- 5.07M
- Turnover
- 18.29M
- Avg Price
- 3.609
- Bid/Ask Ratio
- 88.10%
- Amplitude
- 7.75%
- 52wk High
- 48.360
- Volume Ratio
- 2.05
- Turnover Ratio
- 1.21%
- 52wk Low
- 3.015
- HK Mkt Cap
- 1.47B
- Market CapHKD
- 1.60B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.843
- EPSDynamic
- -0.582
- EPSStatic
- --
- BVPS
- 2.37
- P/B
- 1.48
- HK Shares
- 420.29M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 456.82M
- Min lot size
- 200
- Currency
- HKD
INNOGEN-B Analyst Rating
View moreForecast & Rating
Aug 28, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 13
After a 10.53% weekly rebound faded, the stock reversed intraday: it opened at HK$3.740, printed the session high of HK$3.755 at 09:30 BJ and slid through the morning, touching HK$3.540 at 14:37 BJ before closing at HK$3.585, roughly 4% below the prior close of HK$3.735. Volatility has been sharp, with a HK$3.08 52-week low followed by a 12% snapback, while the company went through board resignations and a strategy committee reshuffle and named a new commercial vice president. Fundamentals show revenue growth alongside continuing losses: Q2 2026 revenue was HK$45.17 million, up 46.07% year on year, but the net loss reached HK$66.68 million, with a -147.61% net margin and -24.51% ROE, against PE of -4.2 and PB of 1.49. The stock is down 88.36% year to date and 92.68% below its 26 January high of HK$48.36, holding above its 20-day MA of 3.458 but below the 60-day MA of 3.698; whether two consecutive quarters of roughly 46% revenue growth can persist remains the swing factor for narrowing losses.
- Nov, 12
Shares fell 3.4% to HK$3.735 in a spike-and-fade session: an early 09:35 high of HK$3.850 gave way to a steady slide and a 14:32 low of HK$3.670, on 7.74 million shares and 1.83% turnover. The pullback interrupts a rebound off the 3 November 52-week low of HK$3.015 that had included a one-day 12% surge, with board resignations and a strategy-committee reshuffle weighing on near-term sentiment. Fundamentals show the tension: Q2 revenue rose 46.07% year on year to HK$45.17 million, yet the HK$66.68 million net loss narrowed only 0.62%, leaving net margin at -147.6% and ROE at -24.51% while commercialization of lead GLP-1 product Yinuoqing stays early-stage. The stock is down 87.72% year to date and sits 92.28% below its 52-week high of HK$48.36, now just above the MA20 of HK$3.462 and close to the MA60 of HK$3.709, on 1.57x PB and a HK$1.71 billion market cap. Though it remains 23.88% above its 52-week low, with a new commercial vice president in place.
- Nov, 10
Innogen (2591.HK) rose 5.84% to HK$3.895, staging a low-open, high-close rebound as discussion of GLP-1 commercialization potential gained attention and the company appointed Jin Bo as vice president to oversee product commercialization. The stock dipped to HK$3.670 at 09:38 BJ, then climbed to HK$4.020 at 13:28 before giving back part of the gain; turnover was HK$49.8 million with a 3.06% turnover rate. Q2 revenue was HK$45.17 million, up 46.07% year on year, while the net loss was HK$66.68 million and the net margin was -147.6%; loss per share was HK$0.146, narrowing 8.58% year on year, leaving the company with revenue growth and a narrower but still unprofitable profile. The price remains in a deep repair zone: down 87.2% year to date, 91.95% below the 52-week high of HK$48.36, but 29.19% above the 52-week low of HK$3.015 set on November 3, and above both MA20 and MA60 at HK$3.46 and HK$3.737; PB is 1.64x. Though reports of a sales head resignation and pressure on domestic GLP-1 product sales remain a reverse factor.
- Nov, 9
Innogen-B rose 1.66% to HK$3.680 in a spike-and-fade session: after the 09:30 open it slipped to 3.610, peaked at 3.905 at 11:50 BJ, then gave back the entire gain into the close on HK$45.39 million of turnover. The move reads as sentiment repair after a steep decline, with a weekly recap showing a 10.53% rebound and Orient Securities reiterating commercialization potential for GLP-1 drugs, which keeps discussion around its core long-acting GLP-1 candidate alive. Fundamentals remain pre-profit: Q2 revenue rose 46.07% YoY to HK$45.17 million while net loss reached HK$66.68 million, with EPS of -HK$0.146 and PB of 1.55. The stock is still down 87.90% YTD and 92.39% below its 52-week high of HK$48.36, trading above the MA20 of 3.462 but below the MA60 of 3.782; though a sales head and several directors resigned earlier, leaving the rebound on a fragile base.
- Nov, 6
Shares of 2591.HK fell 3.7% to HK$3.620 after a low-open, spike-and-fade session that ran from HK$3.500 to HK$3.750 before an afternoon pullback, as the recent resignation of the sales head and several directors kept attention on domestic GLP-1 commercialization challenges. Q2 2026 revenue rose 46.1% year on year to HK$45.2 million, yet the net loss remained HK$66.7 million and EPS was -HK$0.146, showing topline growth has not yet offset losses. The stock sits 20.1% above its 52-week low of HK$3.015 but 92.5% below the January high of HK$48.36 and down 88.1% year to date; it is above the MA20 of HK$3.456 but below the MA60 of HK$3.838. The appointment of former Beijing Dingfeng Bio CEO Jin Bo as vice president adds commercial leadership, though sales-system changes and GLP-1 competition remain in focus.
News
Weekly Review · Weekly Recap | INNOGEN-B -3.53%, consensus target above spot
Market Movers · Innogen climbs 6%
Weekly Review · Weekly Recap | INNOGEN-B +10.53%, consensus target above spot
Market Movers · Innogen drops 6%
Market Movers · Innogen surges 12%
Market Movers · INNOGEN-B hits a new 52-week low, currently trading at $3.08
